Assessing quick tests for action slowing in stroke and cognitive diseases

Diagnostic and Prognostic Value of New Quick Tests of Action Slowing in Stroke and in Cognitive Neurodegenerative Disease

Observational Centre Hospitalier Universitaire, Amiens · NCT05785156

This study is testing new quick tests to see if they can help doctors understand how action slowing in stroke and cognitive disease patients can predict their recovery and diagnose conditions like Alzheimer's earlier.

Quick facts

Study typeObservational
Enrollment129 (estimated)
Ages40 Years to 85 Years
SexAll
SponsorCentre Hospitalier Universitaire, Amiens Academic / other
Drugs / interventionsradiation
Locations1 site (Amiens)
Trial IDNCT05785156 on ClinicalTrials.gov

What this trial studies

This observational study aims to evaluate the diagnostic and prognostic value of new quick tests that measure action slowing in patients with acute stroke and various cognitive neurodegenerative disorders, including Alzheimer's disease and related conditions. The study will investigate how action slowing can predict functional outcomes in stroke patients and its relevance in diagnosing early stages of neurodegenerative diseases. By analyzing the anatomical determinants of action slowing, the research seeks to enhance understanding of these conditions and improve diagnostic methods.

Who should consider this trial

Good fit: Ideal candidates for this study are French-speaking patients aged 40 to 85 with mild to major cognitive disorders related to Alzheimer's disease or other specified neurodegenerative conditions.

Not a fit: Patients with a history of severe brain conditions, previous dementia diagnoses, or significant psychiatric disorders may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved diagnostic tools and prognostic assessments for patients with stroke and cognitive neurodegenerative diseases.

How similar studies have performed: While there is ongoing research into action slowing in brain diseases, this specific approach using new quick tests is relatively novel and has not been extensively tested in prior studies.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients between 40 and 85 years old,
* French native language,
* Social Security affiliation.
* University Memory Clinic for: Mild severity disorder (MMSE\> 19) or major severity disorder related to AD : Albert 2011 criteria ; McKhann 2011
* to MCL according to McKeith criteria
* to FTLD according to Rascovsky 2011 criteria
* BBD according to Armstrong's criteria
* related to PSP according to Höglinger criteria

Exclusion Criteria:

* Mental retardation or guardianship
* Previously diagnosed dementia
* Other current or past brain condition
* severe head trauma
* epilepsy prior to stroke still requiring previous treatment
* Parkinson disease, multiple sclerosis...
* brain tumor or brain radiation therapy
* Current or past schizophrenia or psychosis
* Active or past psychiatric disorders requiring a stay\> 2 days in a specialized environment
* Contra indication to MRI
* Comorbidity with life expectancy \<1 year
* Comorbidity affecting cognition in particular:
* Alcohol (\> 3 glasses / day) or history of alcohol withdrawal syndrome
* opiate or cocaine addiction or opiate withdrawal syndrome
* renal failure (dialysis or creatinine clearance \<30)
* hepatic failure (spontaneous INR\> 1.5 or PT \<60%)
* respiratory failure requiring oxygen therapy
* heart failure (orthopnea\> 2 pillows)
* persistent vigilance disturbances (NIHSS1a score ≤1)
* cancer with paraneoplastic syndrome
* treatment with gold salts, D Penicillamine or other treatment with cognitive effect
* Patient under guardianship or curators or private under public law
* Pregnant and / or lactating wom

Where this trial is running

Amiens

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions StrokeAction SpeedDementia Mild Cognitive ImpairmentAlzheimer Diseaseexecutive processesattentionaction speedDiagnostic
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.